Zurück zur Übersicht
| Cancer immunology research. 2016 Feb 29. pii: 2326-6066.CIR-15-0123. doi: 10.1158/2326-6066.CIR-15-0123 |
| Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. |
| Naidoo J1, Schindler K2, Querfeld C3, Busam KJ4, Cunningham J5, Page DB6, Postow MA7, Weinstein A8, Skripnik Lucas A9, Ciccolini KT10, Quigley EA11, Lesokhin AM12, Paik PK13, Chaft JE14, Segal NH15, D'Angelo SP16, Dickson MA17, Wolchok JD18, Lacouture ME19 |
 Author information
|
|
Abstract Monoclonal antibodies (mAb) targeting immune checkpoint pathways such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) may confer durable disease control in several malignancies. In some patients, immune checkpoint mAb cause cutaneous immune-related adverse events. Although the most commonly reported cutaneous toxicities are mild, a subset may persist despite therapy and can lead to severe or life-threatening toxicity. Autoimmune blistering disorders are not commonly associated with immune checkpoint mAb therapy. We report a case series of patients who developed bullous pemphigoid (BP), an autoimmune process classically attributed to pathologic autoantibody formation and complement deposition. Three patients were identified. Two patients developed BP while receiving the anti-PD-1 mAb nivolumab, and one while receiving the anti-PD-L1 mAb durvalumab. The clinicopathologic features of each patient and rash, and corresponding radiologic findings at the development of the rash and after its treatment, are described. Patients receiving anti-PD-1/PD-L1 mAb may develop immune-related bullous pemphigoid. This may be related to both T-cell and B-cell mediated responses. Referral to dermatology for accurate diagnosis and management is recommended. |
|
©2015 American Association for Cancer Research. |
|
Publikations ID: 26928461 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
